Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 591

1.

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ.

Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007.

PMID:
29551594
2.

Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infection.

Ng SS, Souza-Fonseca-Guimaraes F, Rivera FL, Amante FH, Kumar R, Gao Y, Sheel M, Beattie L, Montes de Oca M, Guillerey C, Edwards CL, Faleiro RJ, Frame T, Bunn PT, Vivier E, Godfrey DI, Pellicci DG, Lopez JA, Andrews KT, Huntington ND, Smyth MJ, McCarthy J, Engwerda CR.

Clin Transl Immunology. 2018 Jan 12;7(1):e1003. doi: 10.1002/cti2.1003. eCollection 2018.

3.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ, Koldej R, Ritchie D.

Blood Adv. 2018 Feb 27;2(4):335-346. doi: 10.1182/bloodadvances.2017015230.

4.

Flt-3L Expansion of Recipient CD8α+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD.

Markey KA, Kuns RD, Browne DJ, Gartlan KH, Robb RJ, Martins JP, Henden AS, Minnie SA, Cheong M, Koyama M, Smyth MJ, Steptoe RJ, Belz GT, Brocker T, Degli-Esposti MA, Lane SW, Hill GR.

Clin Cancer Res. 2018 Apr 1;24(7):1604-1616. doi: 10.1158/1078-0432.CCR-17-2148. Epub 2018 Jan 24.

PMID:
29367429
5.

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Gartlan KH, Varelias A, Koyama M, Robb RJ, Markey KA, Chang K, Wilkinson AN, Smith D, Ullah MA, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Teal BE, Cheong M, Teng MWL, Smyth MJ, Tey SK, MacDonald KPA, Hill GR.

Blood Adv. 2017 Jan 26;1(6):341-351. doi: 10.1182/bloodadvances.2016002980. eCollection 2017 Feb 14.

6.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

PMID:
29229601
7.

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F.

Cancer Res. 2018 Jan 15;78(2):475-488. doi: 10.1158/0008-5472.CAN-17-2415. Epub 2017 Nov 27.

PMID:
29180478
8.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Nov 22;17(12):765. doi: 10.1038/nrc.2017.110. No abstract available.

PMID:
29162946
9.

Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, Kazakoff S, Nutt SL, Takeda K, Hill GR, Waddell N, Smyth MJ.

Cancer Immunol Res. 2017 Dec;5(12):1098-1108. doi: 10.1158/2326-6066.CIR-17-0341. Epub 2017 Oct 25.

PMID:
29070650
10.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Dec;17(12):709-724. doi: 10.1038/nrc.2017.86. Epub 2017 Oct 23. Review. Erratum in: Nat Rev Cancer. 2017 Nov 22;17 (12 ):765.

PMID:
29059149
11.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

PMID:
29045907
12.

Cytokine-driven role of Srebps in killer cell metabolism.

Guillerey C, Smyth MJ.

Nat Immunol. 2017 Oct 18;18(11):1183-1184. doi: 10.1038/ni.3855. No abstract available.

PMID:
29044236
13.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

14.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

PMID:
28855210
15.

Control of Metastasis by NK Cells.

López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L.

Cancer Cell. 2017 Aug 14;32(2):135-154. doi: 10.1016/j.ccell.2017.06.009. Review.

PMID:
28810142
16.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
17.

Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Yan J, Smyth MJ, Teng MWL.

Cold Spring Harb Perspect Biol. 2017 Jul 17. pii: a028530. doi: 10.1101/cshperspect.a028530. [Epub ahead of print]

PMID:
28716888
18.

PD1 functions by inhibiting CD28-mediated co-stimulation.

O'Donnell JS, Smyth MJ, Teng MWL.

Clin Transl Immunology. 2017 May 5;6(5):e138. doi: 10.1038/cti.2017.15. eCollection 2017 May. No abstract available.

19.

Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.

Zhao Y, Ting KK, Li J, Cogger VC, Chen J, Johansson-Percival A, Ngiow SF, Holst J, Grau G, Goel S, Muller T, Dejana E, McCaughan G, Smyth MJ, Ganss R, Vadas MA, Gamble JR.

Cancer Res. 2017 Aug 15;77(16):4434-4447. doi: 10.1158/0008-5472.CAN-16-3129. Epub 2017 Jun 27.

PMID:
28655790
20.

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M.

Cancer Res. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.

PMID:
28652246
21.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ.

Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26.

PMID:
28652244
22.

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Vijayan D, Barkauskas DS, Stannard K, Sult E, Buonpane R, Takeda K, Teng MWL, Sachsenmeier K, Hay C, Smyth MJ.

Oncoimmunology. 2017 Apr 5;6(5):e1312044. doi: 10.1080/2162402X.2017.1312044. eCollection 2017.

23.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ.

Clin Cancer Res. 2017 Oct 1;23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20.

PMID:
28634284
24.

G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.

Casciello F, Al-Ejeh F, Kelly G, Brennan DJ, Ngiow SF, Young A, Stoll T, Windloch K, Hill MM, Smyth MJ, Gannon F, Lee JS.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7077-7082. doi: 10.1073/pnas.1618706114. Epub 2017 Jun 19.

25.

NK cell heparanase controls tumor invasion and immune surveillance.

Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, Goodall KJ, Yee DY, Poon IK, Baschuk N, Souza-Fonseca-Guimaraes F, Hulett MD, Smyth MJ.

J Clin Invest. 2017 Jun 30;127(7):2777-2788. doi: 10.1172/JCI92958. Epub 2017 Jun 5.

26.

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Putz EM, Guillerey C, Kos K, Stannard K, Miles K, Delconte RB, Takeda K, Nicholson SE, Huntington ND, Smyth MJ.

Oncoimmunology. 2017 Feb 7;6(2):e1267892. doi: 10.1080/2162402X.2016.1267892. eCollection 2017.

27.

BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R.

Clin Microbiol Rev. 2017 Apr;30(2):503-528. doi: 10.1128/CMR.00074-16. Review.

28.

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

Dougall WC, Kurtulus S, Smyth MJ, Anderson AC.

Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. Review.

PMID:
28258695
29.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.

PMID:
28249907
30.

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.

Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ.

Nat Commun. 2017 Feb 24;8:14607. doi: 10.1038/ncomms14607.

31.

Multiple approaches to immunotherapy - the new pillar of cancer treatment.

Smyth MJ.

Immunol Cell Biol. 2017 Apr;95(4):323-324. doi: 10.1038/icb.2017.9. No abstract available.

PMID:
28174425
32.

Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice.

Overman J, Fontaine F, Moustaqil M, Mittal D, Sierecki E, Sacilotto N, Zuegg J, Robertson AA, Holmes K, Salim AA, Mamidyala S, Butler MS, Robinson AS, Lesieur E, Johnston W, Alexandrov K, Black BL, Hogan BM, De Val S, Capon RJ, Carroll JS, Bailey TL, Koopman P, Jauch R, Smyth MJ, Cooper MA, Gambin Y, Francois M.

Elife. 2017 Jan 31;6. pii: e21221. doi: 10.7554/eLife.21221.

33.

Targeting cancer-related inflammation in the era of immunotherapy.

Nakamura K, Smyth MJ.

Immunol Cell Biol. 2017 Apr;95(4):325-332. doi: 10.1038/icb.2016.126. Epub 2017 Jan 10. Review.

PMID:
27999432
34.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

PMID:
27965307
35.

Resistance to PD1/PDL1 checkpoint inhibition.

O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. Review.

PMID:
27951441
36.

GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.

Bunting MD, Varelias A, Souza-Fonseca-Guimaraes F, Schuster IS, Lineburg KE, Kuns RD, Fleming P, Locke KR, Huntington ND, Blazar BR, Lane SW, Tey SK, MacDonald KP, Smyth MJ, Degli-Esposti MA, Hill GR.

Blood. 2017 Feb 2;129(5):630-642. doi: 10.1182/blood-2016-08-734020. Epub 2016 Dec 7.

37.

IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage Plasmodium Infection.

Sebina I, James KR, Soon MS, Fogg LG, Best SE, Labastida Rivera F, Montes de Oca M, Amante FH, Thomas BS, Beattie L, Souza-Fonseca-Guimaraes F, Smyth MJ, Hertzog PJ, Hill GR, Hutloff A, Engwerda CR, Haque A.

PLoS Pathog. 2016 Nov 3;12(11):e1005999. doi: 10.1371/journal.ppat.1005999. eCollection 2016 Nov.

38.

Physicochemical properties that control protein aggregation also determine whether a protein is retained or released from necrotic cells.

Samson AL, Ho B, Au AE, Schoenwaelder SM, Smyth MJ, Bottomley SP, Kleifeld O, Medcalf RL.

Open Biol. 2016 Nov;6(11). pii: 160098.

39.

Mouse models in oncoimmunology.

Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G.

Nat Rev Cancer. 2016 Dec;16(12):759-773. doi: 10.1038/nrc.2016.91. Epub 2016 Sep 30. Review.

PMID:
27687979
40.

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

Cancer Res. 2016 Nov 1;76(21):6266-6277. Epub 2016 Sep 9.

41.

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ.

Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. Epub 2016 Sep 12. Review.

42.

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

O'Donnell JS, Smyth MJ, Teng MW.

Genome Med. 2016 Oct 25;8(1):111.

43.

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ, Teng MW.

Cancer Discov. 2016 Dec;6(12):1382-1399. Epub 2016 Sep 23.

44.

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ.

Cancer Cell. 2016 Sep 12;30(3):391-403. doi: 10.1016/j.ccell.2016.06.025.

45.

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Souza-Fonseca-Guimaraes F, Blake SJ, Makkouk A, Chester C, Kohrt HE, Smyth MJ.

Oncoimmunology. 2016 Jun 30;5(7):e1192740. doi: 10.1080/2162402X.2016.1192740. eCollection 2016 Jul.

46.

Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.

Dasari V, Schuessler A, Smith C, Wong Y, Miles JJ, Smyth MJ, Ambalathingal G, Francis R, Campbell S, Chambers D, Khanna R.

Mol Ther Methods Clin Dev. 2016 Aug 24;3:16058. doi: 10.1038/mtm.2016.58. eCollection 2016.

47.

Targeting natural killer cells in cancer immunotherapy.

Guillerey C, Huntington ND, Smyth MJ.

Nat Immunol. 2016 Aug 19;17(9):1025-36. doi: 10.1038/ni.3518. Review.

PMID:
27540992
48.

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW.

Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8.

49.

Checkpoint Immunotherapy: Picking a Winner.

Teng MW, Khanna R, Smyth MJ.

Cancer Discov. 2016 Aug;6(8):818-20. doi: 10.1158/2159-8290.CD-16-0694.

50.

Granzyme M has a critical role in providing innate immune protection in ulcerative colitis.

Souza-Fonseca-Guimaraes F, Krasnova Y, Putoczki T, Miles K, MacDonald KP, Town L, Shi W, Gobe GC, McDade L, Mielke LA, Tye H, Masters SL, Belz GT, Huntington ND, Radford-Smith G, Smyth MJ.

Cell Death Dis. 2016 Jul 21;7:e2302. doi: 10.1038/cddis.2016.215.

Supplemental Content

Loading ...
Support Center